Aarti Pharmalabs Ltd (NSE:AARTIPHARM)

Q1 2026 Aarti Pharmalabs Ltd Earnings Call Transcript

Aug 13, 2025 / 10:30 AM GMT

Release Date Price: ₹790.45 (-7.68%)

Transcript

Key Points

Positve

Aarti Pharmalabs Ltd (BOM:543748) reported a 14% year-over-year increase in EBITDA for Q1 FY26, indicating strong operational performance.
The company achieved a 9% year-over-year increase in profit after tax, demonstrating improved profitability.
Aarti Pharmalabs Ltd (BOM:543748) is expanding its capacity in the Xanthine derivatives segment, with plans to increase production from 5,000 to 9,000 metric tons per annum.
The company is making significant progress in its CDMO/CMO segment, with 60 active projects and a target of 35-40% growth in this area.
Aarti Pharmalabs Ltd (BOM:543748) is focused on regulated markets, with 49% of its API and intermediate business turnover coming from these markets, aligning with its long-term strategy.

Negative

The company's consolidated top line for Q1 FY26 was lower compared to the previous year due to changes in joint venture accounting, which may affect year-over-year comparisons.
Revenue from the USA subsidiary has significantly decreased due to limited business activities, impacting overall sales.
A planned annual shutdown and upgradation of one of the sites affected the standalone top line, resulting in a sales impact of approximately INR 50-20 crores.
Intermediate sales have declined year-over-year, partly due to higher inventory levels and shipping space unavailability.
The company faces geopolitical uncertainties and business challenges due to US tariffs, although current tariffs do not impact its pharma products.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

AARP.NS - Aarti Pharmalabs Ltd
Q1 2026 Aarti Pharmalabs Ltd Earnings Call
Aug 13, 2025 / 10:30AM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Ladies and gentlemen, good day and welcome to RG Pharma labs Q1 FY26 earnings conference call hosted by Nara Wealth Management Limited.

As a reminder, all participant lines will be in the listener mode, and there will be an opportunity to ask questions after the presentation concludes.

Should you need assistance during the conference call, please signal an operator by pressing the star, then 0 on your touchtone phone. Please note that this conference is being recorded.

I now hand the conference over to Mr. Shrikan Akular from Yama Wealth Management Limited.

Thank you and over to you, sir.

--------------------------------------------------------------------------------
Unidentified_2

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

7-Day Free Trial · Cancel Anytime

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.